These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35267618)

  • 81. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].
    Sun XF; Gao XD; Yuan W; Sun JY; Fu M; Xue AW; Li H; Shu P; Fang Y; Hou YY; Shen KT; Sun YH; Qin J; Qin XY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):880-887. PubMed ID: 32927513
    [No Abstract]   [Full Text] [Related]  

  • 82. Clinicopathological and immunohistochemical features of gastointestinal stromal tumors.
    Kang YN; Jung HR; Hwang I
    Cancer Res Treat; 2010 Sep; 42(3):135-43. PubMed ID: 20948918
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.
    Yu L; Favoino E; Wang Y; Ma Y; Deng X; Wang X
    Immunol Res; 2011 Aug; 50(2-3):294-302. PubMed ID: 21717063
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
    Zhang P; Zeng X; Gao J; Liu W; Shuai X; Liu K; Liu X; Cai M; Cai K; Wang G; Tao K
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1290-1295. PubMed ID: 27928802
    [TBL] [Abstract][Full Text] [Related]  

  • 86. NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.
    Rusakiewicz S; Perier A; Semeraro M; Pitt JM; Pogge von Strandmann E; Reiners KS; Aspeslagh S; Pipéroglou C; Vély F; Ivagnes A; Jegou S; Halama N; Chaigneau L; Validire P; Christidis C; Perniceni T; Landi B; Berger A; Isambert N; Domont J; Bonvalot S; Terrier P; Adam J; Coindre JM; Emile JF; Poirier-Colame V; Chaba K; Rocha B; Caignard A; Toubert A; Enot D; Koch J; Marabelle A; Lambert M; Caillat-Zucman S; Leyvraz S; Auclair C; Vivier E; Eggermont A; Borg C; Blay JY; Le Cesne A; Mir O; Zitvogel L
    Oncoimmunology; 2017; 6(1):e1137418. PubMed ID: 28197361
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.
    Liu W; Zeng X; Yin Y; Li C; Yang W; Wan W; Shi L; Wang G; Tao K; Zhang P
    Gastric Cancer; 2020 Jan; 23(1):39-51. PubMed ID: 31197522
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers.
    Li B; Chen H; Yang S; Chen F; Xu L; Li Y; Li M; Zhu C; Shao F; Zhang X; Deng C; Zeng L; He Y; Zhang C
    Mol Cancer; 2023 Apr; 22(1):71. PubMed ID: 37072770
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
    Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
    Front Immunol; 2017; 8():1911. PubMed ID: 29375561
    [TBL] [Abstract][Full Text] [Related]  

  • 90. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.
    Harrer DC; Dörrie J; Schaft N
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779130
    [TBL] [Abstract][Full Text] [Related]  

  • 91. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.
    de Nonneville A; Finetti P; Picard M; Monneur A; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D; Mamessier E; Bertucci F
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267618
    [TBL] [Abstract][Full Text] [Related]  

  • 92. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
    Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
    J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
    [TBL] [Abstract][Full Text] [Related]  

  • 93. PDL1 expression is an independent prognostic factor in localized GIST.
    Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
    Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
    [TBL] [Abstract][Full Text] [Related]  

  • 94. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
    Geldres C; Savoldo B; Hoyos V; Caruana I; Zhang M; Yvon E; Del Vecchio M; Creighton CJ; Ittmann M; Ferrone S; Dotti G
    Clin Cancer Res; 2014 Feb; 20(4):962-71. PubMed ID: 24334762
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
    Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
    J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.